The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 717-722

  Maraldo, M V ^a   Jorgensen M ^a   Brodin, N P ^a,b   Aznar, M C ^a,c   Vogelius, I R ^a   Petersen, P M ^a   Berthelsen, A K ^a   Christensen, C B ^a   Hjalgrim, L L ^a   Specht, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Hodgkin lymphoma; Late effects; Long term survival; Radiotherapy

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CHILD; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INVOLVED FIELD RADIOTHERAPY; INVOLVED NODE RADIOTHERAPY; LUNG; MALE; MANTLE FIELD RADIOTHERAPY; MEDIASTINUM DISEASE; METASTASIS; MODIFIED INVOLVED FIELD RADIOTHERAPY; MORBIDITY; PEDIATRICS; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RISK FACTOR; RISK REDUCTION; SCHOOL CHILD; THYROID GLAND; TREATMENT PLANNING; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; BREAST; CHILD; FEMALE; FOLLOW-UP STUDIES; HEART; HODGKIN DISEASE; HUMANS; LUNG; LYMPH NODES; MALE; NEOPLASMS, SECOND PRIMARY; ORGANS AT RISK; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK ASSESSMENT; THYROID GLAND;

EID: 84893478094     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24861     Document Type: Article

References (22)

1. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: An update from the childhood cancer survivor study. Radiat Res 2010; 174:741-752.
2. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 2011; 117:1806-1816.
3. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208-1215.
4. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55:1145-1152.
5. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227-3232.
6. Dorffel W, Ruhl U, Luders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. J Clin Oncol 2013; 31:1562-1568.
7. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma-A report from the Children's Oncology Group. J Clin Oncol 2012; 30:3174-3180.
8. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 2006; 79:270-277.
9. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008; 88:202-210.
10. Pötter R, Dieckmann K, Hofmann J, et al. Individualisation of radiation fields based on modern sectional imaging within combined treatment of pediatric Hodgkin's disease: Evaluation of 386 patients from the German-Austrian multicenter trial (HD-90). Int J Radiat Oncol Biol Phys 1995; 32: 181(abstr.).
11. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199-4206.
12. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640-652.
13. Brodin NP, Vogelius IR, Maraldo MV, et al. Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 2012; 118:5432-5440.
14. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 83:1232-1237.
15. Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13:79-83.
16. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949-1955.
17. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182-192.
18. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290:465-475.
19. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 2013; 24:2113-2118.
20. Kung FH, Schwartz CL, Ferree CR, et al. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2006; 28:362-368.
21. Maraldo MV, Aznar MC, Vogelius IR, et al. Involved node radiation therapy: An effective alternative in early-stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 85:1057-1065.
22. Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80:199-205.